Abstract
ALS is a neuropathological entity characterised by progressive degeneration of motor neurons in the cortex, brainstem and spinal cord. The onset of ALS is generally observed in late adulthood although juvenile forms do occur albeit rarely (2, 3) . 'Amyotrophic' refers to muscular atrophy, and, 'lateral sclerosis' pertains to the scarring in the lateral aspect of the spinal cord. ALS is a good illustration of clinical heterogeneity;the progression of the disease, exemplified by the development to paralysis, swallowing impairment and respiratory failure may occur within months or years (4) (12) . Increasing knowledge of the role of these genes has changed the landscape of ALS research and allowed further insight into the core pathological mechanisms operant in the development of the disease.
The clinical course of most ALS cases follows a steep curve of deterioration with a rapid and sometimes unpredictable progression to respiratory failure and to the demise of bulbar functions (loss of function of muscles involved in speech and swallowing) (4) . Patients also present with muscle fibre spontaneous activity (fasciculations), weakness and muscle wasting, signs of cortical (upper) motor neuron involvement and cognitive impairment where behavioural changes of the FTD type predominate (11) . Lower motor neuron involvement is potentially the biggest contributor to the neurological decline, affecting the rate of progression to end-stage life-threatening events, clinical milestones such as respiratory failure, the loss of the ability to swallow and the risk of aspiration.
The average delay of 15 to 18 months from onset of symptoms to diagnosis that relies on clinical and neurophysiological observations, depends also on the subtleness of the initial clinical manifestations, which may not be disabling enough to be fully appreciated by the patients or by the examining physicians (13, 14) . The lack of disease-specific biomarkers, to detect early pathology when ALS is suspected, or as disease monitoring tools, further complicates matters. This 'diagnostic latency' reduces the therapeutic window for potential neuroprotective therapies, while neuron-rescuing strategies may lose their greatest chance to work. Further uncertainties surround the definition of the site of initiation of the disease in ALS; whether this is at the neuromuscular junction with an upward development (lower motor neuron first) or the corpus callosum and cortex with a rostrocaudal (front-to-back) progression (upper motor neuron first) (15) (16) (17) .
Various promising biomarkers for ALS are currently being investigated but none of these are diseasespecific or informative enough to allow further speculation on the disease origin or to be used as prognostic indicators (18) . One potential strategy to depict early disease and to monitor its progression makes use of the immune response that is activated during the pathological process.
Here, we discuss the role of the immune pathological changes associated with ALS onset and Evidence for the role of immune responses in ALS is primarily based on post-mortem studies that offer only a late and limited snap-shot of this evolving pathological process. In the central nervous system (CNS), the presence of activated microglia at the site of motor neuron damage has been reported in neuropathological studies and using imaging techniques (23). CD8 + cytotoxic cells and CD4 + T-helper cells are also observed in the ventral horns of the spinal cord, in the anterior and lateral corticospinal tracts and in the motor cortex (24-27). The cascade of molecular events that accompanies the innate immune response may be one of the main driving forces in the unravelling of the pathological process in ALS.
The priming event in ALS pathology: the role of the immune system
Genetic discoveries and the use of animal models have only started to uncover some of the facts surrounding the aetiology of ALS. The study of the immune response linked to the disease may enable a better understanding of the sequence of events leading to motor cell loss, while also representing an exploitable disease biomarker.
Glial cells (e.g. microglia and astrocytes) are non-neuronal cells that support and protect neuron homeostasis. It is proposed that in ALS immune cells, such as microglia-the brain-resident macrophage population deriving from monocyte precursors-become activated in the affected tissues in response to a priming event e.g. misfolded and aggregated proteins (9, 28, 29) . In ALS, like 
Disease initiation and propagation in ALS: an immunological perspective
In neurodegenerative disorders, the onset and propagation of the disease is likely to pre-date the stage when the disease becomes symptomatic. In ALS, experimental evidence indicates that the muscle and the NMJ may be the site of disease manifestation in a very early stage. In animal models of the disease, gene-expression changes in muscle predate any overt motor neuron involvement (56) . In the human pathology, neurophysiological studies have portrayed signs of denervation, NMJ alterations and spontaneous activity from a very early and mildly symptomatic stage of the disease (15) . In contrast to this, more recent suggestions from studies performed using structural Magnetic
Resonance Imaging and tractography suggest a predominant rostro-caudal or cortico-spinal progression of the disease in ALS individuals (57) . Given the lack of a recognisable pre-clinical state in ALS, it is ultimately difficult to define an exact temporal sequence of events and the direction of the pathological spread in ALS.
The expression of factors involved in the immune response in muscle and more specifically at the level of the NMJ is also generally described as an early feature of the disease. In muscle biopsies from ALS patients, antibodies directed against NMJ protein epitopes expressing P/Q-type calcium Equally, ALS has been linked to the up-regulation of most of these cytokines in affected tissues and peripheral blood, including IL-6, TNF-α and TGF-β1 among others. For example, longer disease duration and end-stage disease have been positively correlated with higher TGF-β1 levels (66, 67) . In the human pathology, a conclusive relationship between rate of disease progression or stage and TNF-α levels in biological fluids has not been established (26, (68) (69) (70) . IFN-γ and its downstream factors CXCL10 and MIP-1β may be an example of a protective response in neurodegeneration that can also be measured in the CSF. These markers were negatively correlated with the rate of disease progression in one study, in line with their supposedly neuroprotective function (70), but not conclusively linked to any particular disease state or rate of progression in some others (46, (71) (72) (73) (74) . 
Does the immune response condition the rate of disease progression and survival in ALS?
The immune response to the multifaceted and evolving pathological process in ALS may control the speed of progression of the disease by determining the rate and the extent of motor cell destruction. Whatever combined effect monocytes, T cells and astroglia may have in the affected tissue, the toxic environment surrounding motor cell found in later stages of the disease relates to the predominantly pro-inflammatory milieu in affected tissues (88, 89) . It has been shown that the relative preponderance of T h 1 over T h 2 cytokines, for example, alters the balance between an overall cytoprotective environment towards a cytotoxic one and deepens the harmful cascade of neurotoxic factors like oxygen radicals, excitatory amino acids, arachidonic-acid derivatives and proteases (41, 89) . The upregulation of these pro-inflammatory mediators seems to occur slightly before the 
Humoral immunity in ALS
The humoral response may also have powerful disease-modifying effects in ALS. It has been shown that antibodies against 52,000-to 70,000-dalton proteins detected in brain, cerebellum, and liver as well as in spinal cord are more common in ALS than in control sera but there are no firm data on the nature of the antigens primarily targeted by this enhanced immune reactivity (90) . A recent publication showed the occurrence of a panel of IgG antibodies in serum samples from ALS patients;
and increased disease severity was associated with higher antibody levels (91). Likewise, IgM antibodies against modified (oxidized) wild-type (WT) SOD1 protein, described as aberrantly oxidized, have been reported in ALS patients who exhibit a longer survival compared with subjects lacking these antibodies; anti-SOD1 antibody levels did not correlate with disease severity in either the Alzheimer's or Parkinson's disease cohorts, suggesting that this immune response may be partially ALS-specific and have some prognostic value. In contrast, an immune response against the normal (WT) SOD1 appears to be disadvantageous in sporadic ALS (SALS), possibly because the antioxidizing activity of normal WT-SOD1 is overall beneficial (92) .
From a different angle of observation, serum antibodies against neuron-specific antigens have been identified in patients with autoimmune diseases and in healthy individuals (59, (93) (94) (95) (96) (97) (98) (99) , suggesting that autoimmunity in physiological and pathological states may be enriched with activity potentially critical in neurodegeneration and in ALS. Autoantibodies may have a different impact also in relationship to the levels or avidities (82,100-102) and, within the nervous tissues, they may enter neurons and interact with intracellular targets (99) ( Table 2 ). An increase level of anti-neuronal antibodies, targeting different components of neuronal cells, has been reported in ALS and their expression is reported to be higher in ALS patients with a more severe form of the disease compared with those with a milder condition (103) . To date, immune-modulating and immuno-suppressant treatments have only been partially successful in animal models of the disease, and have been overall disappointing in patients.
Immune responses as biomarkers and targets for therapies
Response to treatments that act on the immune responses may be dependent on the stage of the disease and on the rate of progression of neurodegeneration, both conditioning the type of immunological alteration to be targeted. A personalised and stratified-medicine approach in the choice of treatment acting on the immune response is the strategy most likely to succeed. For (49, 128) . g) Antibodies to LRP4, GM1 Ganglioside, Voltage-gated calcium channels, AchR in presynaptic motor nerve terminals and at NMJs linked to muscle denervation (50, 60, 61, 129 
